Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers' findings advance breast cancer research
July 21st, 2005
Investigators in Germany and the United States have published new breast cancer data. Study 1: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days was compared with doxorubicin and docetaxel every 14 days as preoperative treatment. "Dose-dense and sequential administration of cytotoxic drugs are current approaches to improve outcomes in patients with early-stage breast cancer. This Phase III study investigated 913 women with untreated operable breast cancer (T2-3, N0-2, M0) randomly assigned to receive either doxorubicin 50 mg/m2 plus docetaxel 75 mg/m2 every 14 days for 4 cycles with filgrastim support (ADOC),...
Source: Women's Health Weekly (2005-07-21)
|
